Danaher Corporation $DHR Shares Sold by Hudson Value Partners LLC

Hudson Value Partners LLC cut its position in Danaher Corporation (NYSE:DHR) by 27.0% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 3,635 shares of the conglomerate’s stock after selling 1,342 shares during the quarter. Hudson Value Partners LLC’s holdings in Danaher were worth $718,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in DHR. GHP Investment Advisors Inc. boosted its position in shares of Danaher by 396.0% in the 1st quarter. GHP Investment Advisors Inc. now owns 124 shares of the conglomerate’s stock valued at $25,000 after purchasing an additional 99 shares during the period. Sierra Ocean LLC boosted its position in shares of Danaher by 116.9% in the 1st quarter. Sierra Ocean LLC now owns 141 shares of the conglomerate’s stock valued at $29,000 after purchasing an additional 76 shares during the period. Smallwood Wealth Investment Management LLC acquired a new stake in shares of Danaher in the 1st quarter valued at about $31,000. Dunhill Financial LLC raised its stake in Danaher by 68.4% during the 1st quarter. Dunhill Financial LLC now owns 165 shares of the conglomerate’s stock valued at $34,000 after acquiring an additional 67 shares during the last quarter. Finally, Costello Asset Management INC purchased a new stake in Danaher during the 1st quarter valued at approximately $41,000. 79.05% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, Director Teri List sold 2,778 shares of the firm’s stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $211.06, for a total transaction of $586,324.68. Following the sale, the director owned 20,751 shares in the company, valued at $4,379,706.06. This trade represents a 11.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 11.10% of the stock is owned by company insiders.

Danaher Price Performance

Shares of NYSE:DHR opened at $212.92 on Thursday. The business’s fifty day moving average price is $199.85 and its two-hundred day moving average price is $197.42. The stock has a market cap of $152.46 billion, a PE ratio of 45.30, a price-to-earnings-growth ratio of 2.82 and a beta of 0.77. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.22 and a current ratio of 1.62. Danaher Corporation has a one year low of $171.00 and a one year high of $279.41.

Danaher (NYSE:DHR) last announced its earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 EPS for the quarter, beating analysts’ consensus estimates of $1.64 by $0.16. The firm had revenue of $5.94 billion for the quarter, compared to analysts’ expectations of $5.83 billion. Danaher had a return on equity of 10.70% and a net margin of 14.21%.Danaher’s quarterly revenue was up 3.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.72 EPS. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. On average, analysts forecast that Danaher Corporation will post 7.63 EPS for the current fiscal year.

Danaher Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Friday, September 26th will be issued a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date is Friday, September 26th. Danaher’s dividend payout ratio is 27.23%.

Wall Street Analysts Forecast Growth

Several analysts have commented on DHR shares. Robert W. Baird upped their price objective on Danaher from $225.00 to $226.00 and gave the company an “outperform” rating in a research note on Friday, July 18th. UBS Group reduced their price objective on Danaher from $240.00 to $225.00 and set a “buy” rating for the company in a research note on Wednesday, July 23rd. Barclays restated an “overweight” rating and issued a $225.00 price target (up previously from $215.00) on shares of Danaher in a report on Tuesday, June 24th. Guggenheim restated a “buy” rating and issued a $250.00 price target on shares of Danaher in a report on Wednesday, July 23rd. Finally, Royal Bank Of Canada set a $241.00 price target on Danaher in a report on Tuesday, September 2nd. Seventeen equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, Danaher currently has a consensus rating of “Moderate Buy” and a consensus price target of $245.91.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.